A double-blind, randomized phase II study of S-1 plus resminostat versus S-1 plus placebo in patients with platinum-gemcitabine combination refractory biliary tract cancer (BTC).
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2018
At a glance
- Drugs Resminostat (Primary) ; Gimeracil/oteracil/tegafur
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- Sponsors Yakult Honsha
- 19 Apr 2018 Final results are expected to be available by mid-2020, according to a 4SC media release.
- 09 Apr 2018 Status changed from not yet recruiting to recruiting.
- 21 Mar 2018 According to a 4SC media release, this trial is expected to initiate in in H1 2018.